Primary navigation

    Akynzeo

    Drug - Akynzeo (netupitant and palonosetron)

    April 2015

    Therapeutic area - Nausea and Vomiting

    Approval criteria

    • Patient is receiving moderate to severely emetogenic chemotherapy AND
    • Patient has tried and failed dual therapy with a 5-HT3 antagonist and a substance P/NK1  receptor antagonist

    5-HT3 antagonists and substance P/NK1 receptor antagonists include palonosetron, dolasetron, granisetron, ondansetron and aprepitant

    Questions?

    MHCP Provider Call Center 651-431-2700 or 800-366-5411

    back to top